Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ELI LILLY AND COMPANY

(LLY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Eli Lilly and : , Incyte Say FDA Extends Review of Dermatitis Drug

04/06/2021 | 04:51pm EDT


© MT Newswires 2021
All news about ELI LILLY AND COMPANY
05/06Regeneron expects continuing demand for its COVID-19 therapy
RE
05/06ELI LILLY AND  : Lilly collaborates internationally with leading diabetes techno..
PR
05/05MARKET CHATTER : Eli Lilly Employees Reportedly Accuse US Factory Executive of A..
MT
05/05ELI LILLY AND  : Lilly executive accused of rewriting documents to downplay issu..
AQ
05/05ELI LILLY AND  : Lilly to Participate in Bank of America Securities 2021 Health ..
PR
05/05MARKET CHATTER : Eli Lilly Employees Accuse Factory Executive of Altering Regula..
MT
05/05ELI LILLY AND  : Submission of Matters to a Vote of Security Holders
PU
05/05ELI LILLY & CO  : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
05/04ELI LILLY AND  : Donating COVID-19 Baricitinib Tablets to India
MT
05/04ELI LILLY AND  : Updates Social Commitments, Pledges Carbon Neutrality By 2030
MT
More news
Financials (USD)
Sales 2021 27 299 M - -
Net income 2021 6 776 M - -
Net Debt 2021 11 229 M - -
P/E ratio 2021 26,6x
Yield 2021 1,69%
Capitalization 178 B 178 B -
EV / Sales 2021 6,92x
EV / Sales 2022 6,72x
Nbr of Employees 35 000
Free-Float 99,5%
Chart ELI LILLY AND COMPANY
Duration : Period :
Eli Lilly and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ELI LILLY AND COMPANY
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 214,04 $
Last Close Price 195,42 $
Spread / Highest target 29,0%
Spread / Average Target 9,53%
Spread / Lowest Target -10,4%
EPS Revisions
Managers and Directors
NameTitle
David A. Ricks Chairman, President & Chief Executive Officer
Anat Ashkenazi Chief Financial Officer & Senior Vice President
Timothy J. Garnett Chief Medical Officer & VP-Global Medical
Aarti S. Shah Senior VP, Chief Information & Digital Officer
Daniel M. Skovronsky Chief Scientific Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
ELI LILLY AND COMPANY15.74%177 642
JOHNSON & JOHNSON7.07%443 727
ROCHE HOLDING AG-1.88%289 958
PFIZER, INC.6.47%220 784
ABBVIE INC.8.03%204 279
MERCK & CO., INC.-4.14%198 539